Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time after COVID-19 as well as efficiency against novel variants are poorly characterized.
METHODS: In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3 and 6 months postinfection. We performed quantitative neutralization experiments on top of high-throughput serological assays evaluating anti-spike (S) and anti-nucleocapsid (NP) immunoglobulin G (IgG).
RESULTS: Levels of seroneutralization and IgG rates against the ancestral strain decreased significantly over time. After 6 months, 2.8% of the patients had a negative serological status for both anti-S and anti-NP IgG. However, all sera had a persistent and effective neutralizing effect against SARS-CoV-2. IgG levels correlated with seroneutralization, and this correlation was stronger for anti-S than for anti-NP antibodies. The level of seroneutralization quantified at 6 months correlated with markers of initial severity, notably admission to intensive care units and the need for mechanical invasive ventilation. In addition, sera collected at 6 months were tested against multiple SARS-CoV-2 variants and showed efficient neutralizing effects against the D614G, B.1.1.7, and P.1 variants but significantly weaker activity against the B.1.351 variant.
CONCLUSIONS: Decrease in IgG rates and serological assays becoming negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the ancestral strain and the D614G, B.1.1.7, and P.1 variants for at least 6 months in patients previously hospitalized for COVID-19. A weaker protection was, however, observed for the B.1.351 variant.
| Errataetall: |
CommentIn: Clin Infect Dis. 2021 Sep 15;73(6):e1345-e1347. - PMID 33905478 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 6 vom: 15. Sept., Seite e1337-e1344 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Betton, Maureen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 23.09.2021 Date Revised 29.11.2021 published: Print CommentIn: Clin Infect Dis. 2021 Sep 15;73(6):e1345-e1347. - PMID 33905478 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciab308 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324060513 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324060513 | ||
| 003 | DE-627 | ||
| 005 | 20231225185520.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciab308 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324060513 | ||
| 035 | |a (NLM)33851216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Betton, Maureen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.09.2021 | ||
| 500 | |a Date Revised 29.11.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Infect Dis. 2021 Sep 15;73(6):e1345-e1347. - PMID 33905478 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time after COVID-19 as well as efficiency against novel variants are poorly characterized | ||
| 520 | |a METHODS: In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3 and 6 months postinfection. We performed quantitative neutralization experiments on top of high-throughput serological assays evaluating anti-spike (S) and anti-nucleocapsid (NP) immunoglobulin G (IgG) | ||
| 520 | |a RESULTS: Levels of seroneutralization and IgG rates against the ancestral strain decreased significantly over time. After 6 months, 2.8% of the patients had a negative serological status for both anti-S and anti-NP IgG. However, all sera had a persistent and effective neutralizing effect against SARS-CoV-2. IgG levels correlated with seroneutralization, and this correlation was stronger for anti-S than for anti-NP antibodies. The level of seroneutralization quantified at 6 months correlated with markers of initial severity, notably admission to intensive care units and the need for mechanical invasive ventilation. In addition, sera collected at 6 months were tested against multiple SARS-CoV-2 variants and showed efficient neutralizing effects against the D614G, B.1.1.7, and P.1 variants but significantly weaker activity against the B.1.351 variant | ||
| 520 | |a CONCLUSIONS: Decrease in IgG rates and serological assays becoming negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the ancestral strain and the D614G, B.1.1.7, and P.1 variants for at least 6 months in patients previously hospitalized for COVID-19. A weaker protection was, however, observed for the B.1.351 variant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 700 | 1 | |a Livrozet, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Planas, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Fayol, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Monel, Blandine |e verfasserin |4 aut | |
| 700 | 1 | |a Védie, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Bruel, Timothée |e verfasserin |4 aut | |
| 700 | 1 | |a Tartour, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Robillard, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Manuguerra, Jean-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchard, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosn, Jade |e verfasserin |4 aut | |
| 700 | 1 | |a Visseaux, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Péré, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Lebeaux, David |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Veyer, David |e verfasserin |4 aut | |
| 700 | 1 | |a Hulot, Jean-Sébastien |e verfasserin |4 aut | |
| 700 | 0 | |a French COVID Cohort Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Abel, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Andrejak, Claire |e investigator |4 oth | |
| 700 | 1 | |a Angoulvant, François |e investigator |4 oth | |
| 700 | 1 | |a Bachelet, Delphine |e investigator |4 oth | |
| 700 | 1 | |a Bhavsar, Krishna |e investigator |4 oth | |
| 700 | 1 | |a Bouadma, Lila |e investigator |4 oth | |
| 700 | 1 | |a Chair, Anissa |e investigator |4 oth | |
| 700 | 1 | |a Couffignal, Camille |e investigator |4 oth | |
| 700 | 1 | |a da Silveira, Charlene |e investigator |4 oth | |
| 700 | 1 | |a Debray, Marie-Pierre |e investigator |4 oth | |
| 700 | 1 | |a Descamps, Diane |e investigator |4 oth | |
| 700 | 1 | |a Duval, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Eloy, Philippine |e investigator |4 oth | |
| 700 | 1 | |a Esposito-Farese, Marina |e investigator |4 oth | |
| 700 | 1 | |a Ettalhaoui, Nadia |e investigator |4 oth | |
| 700 | 1 | |a Gault, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Ghosn, Jade |e investigator |4 oth | |
| 700 | 1 | |a Gorenne, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Hoffmann, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Kafif, Ouifiya |e investigator |4 oth | |
| 700 | 1 | |a Kali, Sabrina |e investigator |4 oth | |
| 700 | 1 | |a Khalil, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Laouénan, Cédric |e investigator |4 oth | |
| 700 | 1 | |a Laribi, Samira |e investigator |4 oth | |
| 700 | 1 | |a Le, Minh |e investigator |4 oth | |
| 700 | 1 | |a Le Hingrat, Quentin |e investigator |4 oth | |
| 700 | 1 | |a Lescure, François-Xavier |e investigator |4 oth | |
| 700 | 1 | |a Lucet, Jean Christophe |e investigator |4 oth | |
| 700 | 1 | |a Mentré, France |e investigator |4 oth | |
| 700 | 1 | |a Mullaert, Jimmy |e investigator |4 oth | |
| 700 | 1 | |a Peiffer-Smadja, Nathan |e investigator |4 oth | |
| 700 | 1 | |a Peytavin, Gilles |e investigator |4 oth | |
| 700 | 1 | |a Roy, Carine |e investigator |4 oth | |
| 700 | 1 | |a Schneider, Marion |e investigator |4 oth | |
| 700 | 1 | |a Si Mohammed, Nassima |e investigator |4 oth | |
| 700 | 1 | |a Tagherset, Lysa |e investigator |4 oth | |
| 700 | 1 | |a Tardivon, Coralie |e investigator |4 oth | |
| 700 | 1 | |a Tellier, Marie-Capucine |e investigator |4 oth | |
| 700 | 1 | |a Timsit, Jean-François |e investigator |4 oth | |
| 700 | 1 | |a Trioux, Théo |e investigator |4 oth | |
| 700 | 1 | |a Tubiana, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Visseaux, Benoit |e investigator |4 oth | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e investigator |4 oth | |
| 700 | 1 | |a Basmaci, Romain |e investigator |4 oth | |
| 700 | 1 | |a Picone, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Behilill, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a van der Werf, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Enouf, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Mouquet, Hugo |e investigator |4 oth | |
| 700 | 1 | |a Beluze, Marine |e investigator |4 oth | |
| 700 | 1 | |a Benkerrou, Dehbia |e investigator |4 oth | |
| 700 | 1 | |a Dorival, Céline |e investigator |4 oth | |
| 700 | 1 | |a Téoulé, François |e investigator |4 oth | |
| 700 | 1 | |a Meziane, Amina |e investigator |4 oth | |
| 700 | 1 | |a Bompart, François |e investigator |4 oth | |
| 700 | 1 | |a Bouscambert, Maude |e investigator |4 oth | |
| 700 | 1 | |a Cervantes-Gonzalez, Minerva |e investigator |4 oth | |
| 700 | 1 | |a d'Ortenzio, Eric |e investigator |4 oth | |
| 700 | 1 | |a Puéchal, Oriane |e investigator |4 oth | |
| 700 | 1 | |a Semaille, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Chirouze, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Coelho, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Couffin-Cadiergues, Sandrine |e investigator |4 oth | |
| 700 | 1 | |a Esperou, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Houas, Ikram |e investigator |4 oth | |
| 700 | 1 | |a Jaafoura, Salma |e investigator |4 oth | |
| 700 | 1 | |a Papadopoulos, Aurélie |e investigator |4 oth | |
| 700 | 1 | |a Deplanque, Dominique |e investigator |4 oth | |
| 700 | 1 | |a Desvallée, Mathilde |e investigator |4 oth | |
| 700 | 1 | |a Khan, Coralie |e investigator |4 oth | |
| 700 | 1 | |a Diallo, Alpha |e investigator |4 oth | |
| 700 | 1 | |a Bartoli, Marie |e investigator |4 oth | |
| 700 | 1 | |a Le Mestre, Soizic |e investigator |4 oth | |
| 700 | 1 | |a Mercier, Noémie |e investigator |4 oth | |
| 700 | 1 | |a Paul, Christelle |e investigator |4 oth | |
| 700 | 1 | |a Petrov-Sanchez, Ventzislava |e investigator |4 oth | |
| 700 | 1 | |a Diouf, Alphonsine |e investigator |4 oth | |
| 700 | 1 | |a Hoctin, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Mambert, Marina |e investigator |4 oth | |
| 700 | 1 | |a Dubos, François |e investigator |4 oth | |
| 700 | 1 | |a Etienne, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Gaymard, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Gigante, Tristan |e investigator |4 oth | |
| 700 | 1 | |a Gilg, Morgane |e investigator |4 oth | |
| 700 | 1 | |a Rossignol, Bénédicte |e investigator |4 oth | |
| 700 | 1 | |a Guedj, Jérémie |e investigator |4 oth | |
| 700 | 1 | |a Le Nagard, Hervé |e investigator |4 oth | |
| 700 | 1 | |a Lingas, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Neant, Nadège |e investigator |4 oth | |
| 700 | 1 | |a Hulot, Jean-Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Kaguelidou, Florentia |e investigator |4 oth | |
| 700 | 1 | |a Pages, Justine |e investigator |4 oth | |
| 700 | 1 | |a Levy, Yves |e investigator |4 oth | |
| 700 | 1 | |a Wiedemann, Aurélie |e investigator |4 oth | |
| 700 | 1 | |a Levy-Marchal, Claire |e investigator |4 oth | |
| 700 | 1 | |a Lina, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Rosa-Calatrava, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Terrier, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Malvy, Denis |e investigator |4 oth | |
| 700 | 1 | |a Noret, Marion |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 6 vom: 15. Sept., Seite e1337-e1344 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:6 |g day:15 |g month:09 |g pages:e1337-e1344 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciab308 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 6 |b 15 |c 09 |h e1337-e1344 | ||